WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
Adds background on telehealth companies in paragraph 3, price in paragraph 5
Oct 8 (Reuters) -WeightWatchers WW.O said on Tuesday it would offer a compounded version of Novo Nordisk's NOVOb.CO popular obesity drug Wegovy as part of its weight-management programs.
Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's LLY.N Zepbound, shown to help patients lose as much as 20% of weight on average, has led to their shortages that allowed drug compounders to produce them under U.S. regulations.
Multiple telehealth companies, including Noom and Hims & Hers Health HIMS.N, offer compounded versions of semaglutide, the chemical name of Novo's Wegovy and its diabetes drug Ozempic, as patients look for alternatives amid their shortage.
Drug compounding refers to the practice of combining, mixing or altering drug ingredients to create a medicine tailored for an individual patient's need, according to the U.S. Food and Drug Administration.
The company, also known as WW International, said the new offering would start at $129.
Its shares were up 3.8% in late-morning trading, paring early gains.
"Given the ongoing shortages of branded medications such as Ozempic and Wegovy, WeightWatchers is committed to ensuring our members still have access to effective alternatives," CEO Tara Comonte said in a statement.
Outsourcing Facilities Association, a drug compounding industry group, sued the FDA on Monday over its decision to take Eli Lilly's blockbuster weight-loss and diabetes drugs off its list of medicines in short supply last week.
Novo's Wegovy and Ozempic are still on that list.
The compounding group claimed the FDA removed Lilly's tirzepatide, the key ingredient in its drugs Mounjaro and Zepbound, from the list even though it remains in short supply.
Lilly said in August it had begun selling vials of its Zepbound at $399 for a month's supply through its direct-to-consumer website.
Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
